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Clostridium difficile (C. difficile) is regarded as the major cause of infectious 
diarrhea in humans after antimicrobial treatment. C. difficile has been reported to be 
widely isolated from food animals and meat. The main purpose of this study was to 
characterize C. difficile isolates from retail fresh vegetable (lettuce), test the 
antibiotic-resistance property using five common clinical-selected antibiotics 
(metronidazole, vancomycin, clindamycin, erythromycin, and cefotaxime). Lettuces 
(grown in California, Arkansas, and Louisiana) were purchased from retail stores. 
Toxigenic C. difficile was isolated from 13.8% (41/297) of the lettuce samples. 
Among the toxigenic isolates, 82.9% (34/41) only produce toxin B, and 17.1% (7/41) 
produced both toxin A and toxin B. Under the treatment of the five antibiotics, the 
virulence C. difficile isolates were identified as having antibiotic resistance to 
metronidazole, vancomycin, and erythromycin. The present study reports the highest 
toxigenic C. difficile yield rate from varieties of retail vegetables (lettuce) in the USA. 
The antibiotic resistance to metronidazole, vancomycin, and erythromycin of the 






CHAPTER I．Introduction to Clostridium difficile 
1.1 Clostridium difficile  
Clostridium difficile (C. difficile), a species of Gram-positive, spore-forming, 
and anaerobic bacteria, causes diarrhea and more serious intestinal conditions such as 
pseudomembranous colitis in humans (Monaghan et al. 2013). The name given to this 
organism was because it was difficult to isolate and grew slowly when being cultured. 
According to the Center for Disease Control and Prevention (CDC), C. difficile has 
been listed as an immediate health threat, and C. difficile infection (CDI) induces 
250,000 hospitalizations and 14,000 deaths per year. There are typically three 
manifestations of CDI development: asymptomatic carrier state, colitis with or 
without pseudomembranes, and fulminant colitis.  
1.2 History of C. difficile 
C. difficile was first identified in 1935 in the common intestinal colonic flora 
of newborn infants(Hall and O'Toole, 390-402). At first, it was known as Bacillus 
difficile, because it was difficult to grow outside of anaerobic broth culture. It was so 
frequently isolated from the feces of newborn infants that it was regarded as part of 
the infants’ gut microbiota at that time. However, subsequent studies indicated its pure 
broth cultures could lead to experimental animal death if being injected(Snyder 1937). 
Thus, C. difficile was believed as non-pathogenic to humans. Not until the late 1970s 
were the biological activities of its toxins defined, and C. difficile toxins were linked 
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to pseudomembranous colitis (PMC), proving it to be a human pathogen(Bartlett et al. 
1978a).  
In 1893, the definition of pseudomembranous colitis (PMC) was first raised by 
Finney (Bartlett et al. 1978b) as a post-operative complication. PMC (Figure 1) is 
described as multiple yellow discrete patches (Figure 1) growing on the surface of 
colon mucosal (Nelson et al. 1994) ,which microscopically reveals partially destroyed 
mucosal layer glands covered with fibrin and inflammatory polymorph nuclear 
leukocytes (Nelson et al. 1994). The residues of colonic glands are able to become 
necrotic and inflamed. Besides, the submucosa may also become contaminated with 
the increasing amount of vasculature and inflammatory cells, which are responsible 
for water loss and subsequent diarrhea (Nelson et al. 1994). The pseudomembrane is 
considered as having the ability of growing over and replacing the normal colonic 
mucosa concerning bacterial toxins (Bartlett et al. 1978b). 
PMC was not commonly diagnosed until the increasing usage of antimicrobial 
agents in the 1950s, when PMC was known as a common complication with high 
mortality rates (Nelson et al. 1994). At first, Staphylococcus aureus was regarded as 
Figure 1. Pseudomembranous colitis.  
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the reason to cause PMC by the Gram staining of plaques. Later, the stains revealed 
many Gram positive cocci in clusters (Bartlett et al. 1978b).  This theory was also 
supported by the knowledge of staphylococcal enterotoxins produced by S. aureus 
causing enteric disease, and the clinical improvement when treating those patients 
suffering from PMC with vancomycin instead (Bartlett et al. 1978b). Because of the 
failure of imitating the effects that were occurring in humans using animal models 
infected with S. aureus, other potential causes of the origin of PMC were pursued 
continuously (Bartlett et al. 1978b). The true explanation of these infections stayed 
unknown, and was not being associated with C. difficile until two decades later when 
the connection between the toxins A and B of C. difficile and PMC was revealed 
(Bartlett et al. 1978b). 
In the 1960s, anaerobic bacteria were related to the formation of aposteme, 
and several new antibiotics were developed to target them. Clindamycin was 
especially effective for intestinal infections caused by anaerobic bacteria (Bignardi 
1998). However, there was a common side effect of clindamycin treatment---diarrhea, 
which some patients severely suffered from and progressed to PMC in a lot of cases 
(Bignardi 1998). This antibiotic-associated diarrhea was not only seen with 
clindamycin, but also with other broad spectrum antimicrobials, so it was named as 
antibiotic associated diarrhea (AAD) (Bignardi 1998). After C. difficile toxins were 
identified in patients suffering from colitis, the linkage among C. difficile, antibiotic 
usage and PMC was established (Bartlett et al. 1978b). 
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Based on the association of antimicrobial use, PMC and C. difficile, 
researchers began to exploring a toxin responsible for the diarrhea associated with C. 
difficile infection (CDI). First, toxin B was confirmed by neutralizing the toxin’s 
effect by using the antitoxin of Clostridium sordellii. Toxin B was lethal in animal 
testing, the ability of causing severe hemorrhage, and mucosal edema in the cecum of 
laboratory animals. During the process of purifying the toxin, a second toxin showed 
up, toxin A. However, injecting an equal amount of toxin A followed by the same 
route was not lethal in animal models, and only brought about focal hemorrhage 
(Taylor, Thorne, and Bartlett 1981). Purified toxin A was able to result in a disease 
pathology similar to CDI, while testing animals in the same condition, toxin B had no 
effect at that time. Thus, Toxin B was thought to have an effect on test animals only 
with the presence of toxin A (Mitchell et al. 1986b, Taylor, Thorne, and Bartlett 1981). 
However, a toxin A negative, toxin B positive strain was isolated in a CDI outbreak in 
Canada in 1998, and later these strains have been discovered frequently (Drudy, 
Fanning, and Kyne 2007). So it has been regarded that both toxins are now considered 
responsible for the pathology, although toxin A positive, toxin B negative strains have 
not been found to be naturally present. In 2009, laboratory created toxin-A positive, 
toxin B-negative mutants showing reduced pathology in a hamster model, where 
pathology in hamsters caused by toxin A-negative, toxin B positive mutants remained 
unaffected in severity (Lyras, O’Connor, et al. 2009). This result indicates that toxin B 
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is essential for C. difficile disease, and synergy effect along with toxin A may not be 
necessary (Lyras, O’Connor, et al. 2009). 
1.3 Toxins of C. difficile 
Those strains lack of the ability of producing toxins are not considered 
pathogenic. When nutrients are abundant, toxin production will be inhibited, while 
during the essential nutrients shortage, particularly biotin, toxin production will cause 
intestinal epithelial cells to rupture, releasing nutrients (Yamakawa et al. 1996). 
Pathogenic C. difficile produces two protein exotoxins, Toxin A, comprised of 2710 
residues (308.0 kDa), and toxin B, comprised of 2366 residues (269.6 kDa) (Kelly and 
LaMont 1998). Toxin A and toxin B (also called TcdA and TcdB), belonging to the 
large clostridial cytotoxins (LCT), can cause animal death, while toxin A, called 
enterotoxin, has been proven to cause fluid accumulation, and severe epithelial 
damage with hemorrhage and diarrhea in rabbit ileal loops (Mitchell et al. 1986a, 
Torres and Lonnroth 1989). After toxin A and toxin B gain access into cells, they exert 
an alteration of Rho proteins (a family of GTP-binding protein associated with actin 
polymerization, cytoskeletal architecture, and cell movement) and finally result in the 
depolymerization of actin filaments, disruption of the cytoskeleton, cell rounding, and 
cell death (Kelly and LaMont 1998). Both A and B toxins contain four domains 
(Figure 2): a receptor binding domain; an enzymatic domain; an autoproteolytic 
cleavage during toxin-processing domain; and a hydrophobic translocation domain 
responsible for transferring the enzymatic domain into the cytosol (Belyi and Aktories 
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2010). The C terminal receptor binding domains of the two toxins are different, 
allowing the toxins to attach to the corresponding intestinal epithelial cell receptors 
toxin A to the apical surface receptors, and toxin B to the basolateral surface receptors 
(Jank, Giesemann, and Aktories 2007).  
 
Figure 2. The model of toxin A and toxin B. 
The genes encoding toxin A and toxin B are part of the pathogenicity locus 
(PaLoc), a 19.6kb chromosomal segment consists of TcdA-E genes (Figure 3) which 
provides a base for C. difficile PCR genotyping (Warny et al. 2005). These genes 
encode toxin A (TcdA), toxin B (TcdB), a negative regulator (TcdC), a positive 
regulator (TcdD), and a holing-like protein (TcdE). Transcription analysis studies 
indicate that TcdA, B, D, E are transcribed both monocistronically and 
polycistronically (Hundsberger et al. 1997). This mode of transcription is clearly the 
prior condition of a high production of toxin A and toxin B (Hundsberger et al. 1997). 
While, during the logarithmic phase, the TcdC gene has strong expression, and the 
other four genes are in weak transcription. The inverse is observed during the 
stationary phase, implicating that TcdC negatively regulates toxin expression 
(Hundsberger et al. 1997). Yet, the presence of TcdC genes, including TcdA and TcdB, 
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has also been found outside the PaLoc in several C. difficile strains. As TcdD 
increases with TcdA, B, E, TcdD is recognized as a positive regulation promoting 
toxin expression. Thus, TcdC and TcdD might be key factors regulating the production 
of the two toxins.  
 
Figure 3. The pathogenicity locus. 
Both toxins stay stable from -20 to 37⁰C, but will lose activity at 56⁰C 
(Sullivan, Pellett, and Wilkins 1982). Yet, neither toxin has effect on intracellular 
levels of cyclic AMP or GMP (Kelly and LaMont 1998). In addition, neither toxin is 
found to have association with spore production (Arnon et al. 1984). One of the 
physicochemical properties of toxin A, after purification, is its large size (Lyerly, 
Krivan, and Wilkins 1988). It can cause huge damage to gut mucosa (Mitchell et al. 
1986a).  
Toxin B, as a cytotoxin, is believed to be as lethal as toxin A, but less stable 
than toxin A (Arnon et al. 1984, Banno et al. 1984). It brings generous nonspecific 
responses in mammalian cells, such as the loss of intracellular potassium, decrease in 
protein synthesis, and decrease in synthesis of ribonucleic and deoxyribonucleic acids 
(Pothoulakis et al. 1986, Rihn et al. 1985). It induces rounding cells 100-10000 times 
more severe than toxin A in many cell types (Chaves-Olarte et al. 1997).  
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C. difficile transferase (CDT), a third toxin (aka, binary toxin), is an 
actin-specific ADP-ribosyltransferase; it was first proposed by Popoff et al. together 
with a few C. difficile strains in 1988 (Perelle et al. 1997, Popoff et al. 1988, Stubbs et 
al. 2000). Other similar toxins are produced by other species such as: iota toxin from 
Clostridium perfringens (Stiles and Wilkins 1986),Clostridium botulinum 
ADPribosyltransferase C3 (Aktories, Weller, and Chhatwal 1987),and Clostridium 
spiroforme toxin (CST) (Simpson et al. 1989). The CDT toxin structure is composed 
of two separate proteins encoded by genes cdtA and cdtB, where A is the enzyme 
component and B is the receptor binding and translocation component. Cells 
contaminated by CDT toxin present depolymerization of F actin, leading to cell 
rounding. Additionally, the formation of surface microtubules displays in these cells 
that have been shown to raise the possibility of C. difficile adherence. This increased 
adherence to the cell surfaces may promote colonization, adding to the virulence of 
these CDT producing strains (Schwan et al. 2009). It was shown that C. difficile 
strains which produce CDT toxin in addition to toxins A and B tend to be more 
virulent, especially the hypervirulent PCR ribotype 027 and 078 strains. Nonetheless, 
some C. difficile strains only produce CDT toxin without toxins A and B; there is no 
strong evidence indicating a hypervirulent strain (Stubbs et al. 2000). 
1.4 Sporulation of C. difficile 
C. difficile’s ability to produce infectious endospores assists both its 
survivability outside and inside of its host. Sporulation forms when reproduction of 
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vegetative cells suffers from nutrient deprivation or undesirable conditions. The 
metabolically inactive property of the spores gives them the ability of being resistant 
to antimicrobial treatments, heat, radiation, desiccation and chemical treatments. Thus, 
spores are resistant to the majority of cleaning products used in healthcare facilities 
(Gerding, Muto, and Owens 2008). The spore formation of C. difficile grants the 
bacteria fecal oral transmission in healthcare facilities, either directly from patient to 
patient, or by transmission from the hands of health care personnel (Lawley et al. 
2009, Underwood et al. 2009). Researchers found spores are frequently spread by 
flushing toilets or changing the bed sheets contaminated with feces from C. difficile 
patients (Best et al. 2010, Donskey 2010, Roberts et al. 2008). 
Prokaryote sporulation is an evolutionary performance to protect species 
survival. Spore formation allows cells to wait until environmental conditions become 
suitable for them to switch back to their vegetative form and continue growing (De 
Hoon, Eichenberger, and Vitkup 2010). The process of sporulation has been 
thoroughly studied in Bacillus subtilis; its process may also be applied to C. difficile.  
Sporulation can be divided into seven separate stages (Figure 4). The process starts 
with stage I, where the vegetative cell grows in size and replicates its DNA followed 
normally by cell division resulting in stage 0. Different from a normal binary cell 
division, the cell is divided into two unequal parts called stage II during the 
sporulation process. The larger portion is considered as the mother cell, and the 
smaller portion is the fore spore. In stage III, the fore spore then becomes immersed in 
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the mother cell, continuing the process of growing to a mature spore at the same time. 
In stage IV, peptidoglycan forms the cortex layer of the fore pore, separating the two 
cells. Calcium dipicolinate synthesized by the mother cell is concentrated in the spore 
core, stabilizing the DNA. Diplocolinic acid and calcium enable the spore to become 
resistance to heat and oxidizing agents (Setlow 2007). During stage V, an outer 
protein layer is formed to coat the outer membrane. The spore turns to be mature in 
stage VI, along with finishing coat synthesis, dehydration, and lysis of the mother cell 
wall by the action of lytic proteins. Accordingly, the dormant spore is released (De 
Hoon, Eichenberger, and Vitkup 2010, Paredes, Alsaker, and Papoutsakis 2005). 
 





C. difficile infection stands in the first place in the cause of antibiotic 
associated diarrhea, having a percentage of 10-25% of all cases (Bartlett 2002). 
Carriage and colonization rates vary widely between different patient groups. Among 
the normal adult population, C. difficile asymptomatic carriage is estimated at 2-3%, 
but much higher in those frequently exposed to healthcare environments (Barbut and 
Petit 2001). Concerning the newborns, they are highly susceptible to acquiring C. 
difficile, given the fact that they have no protective normal gut flora to inhibit 
colonization. Normally, the acquisition of C. difficile in newborns is considered to be 
gained from the child’s mother flora or the newborn nursery environment 
(TABAQCHALI et al. 1984). Carriage rates in newborns born in hospitals have been 
appeared to be as high as 70% (Kato et al. 1994, TABAQCHALI et al. 1984). 
Carriage rates are also showed to be higher in healthcare providers and high risk 
patients that have been hospitalized or received antibiotics (Barbut and Petit 2001, 
Giannasca and Warny 2004). It is reported that approximately one-third of the 
long-term healthcare facility residents asymptomatically carry C. difficile (Simor et al. 
2002). 
1.6 Risk factors associated with C. difficile infection (CDI) 
The key risk factor associated with development of CDI is the treatment with 
antibiotics. More than 90% of all CDI cases happen during or following treatment 
with antibiotics (Barbut and Petit 2001). Apart from aminoglycosides, almost every 
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other antibiotic would lead to some risk of progression from asymptomatic 
colonization to CDI (Sunenshine and McDonald 2006). Exposure to antibiotics may 
develop to CDI, but the infection could be delayed for up to 8 weeks after antibiotics 
are consumed (Johnson and Gerding 1998b, Kelly, Pothoulakis, and LaMont 1994). A 
majority of CDI cases involved the use of clindamycin, fluoroquinolones, or third 
generation cephalosporins (Gerding 2004). It is supported that limiting the use of 
these antibiotics could significantly reduce the healthcare acquired infections (HAI) 
concerning C. difficile (Carling et al. 2003). It is vital for individual healthcare 
institutions to be aware of the sensitivity and resistance patterns of C. difficile isolates 
that rely on their environment and patient population. If an isolate in an institution 
shows its resistant to clindamycin, then the use of clindamycin should be highly 
restricted (Owens et al. 2008, Pear et al. 1994). On the other side, if a patient’s C. 
difficile organisms are routinely sensitive to a specific antimicrobial, then the use of 
that antibiotic should be encouraged (Donskey 2010).  
There are several high risk populations, whose who are the elderly, immune 
dysfunctional, pregnant, and those frequently exposed to healthcare environments. 
Patients older than 65 years of age or with severe underlying illness are vulnerable to 
CDI (Barbut and Petit 2001, Bignardi 1998). The reason of this may also be 
associated with more frequency of hospitalization, decreasing immune function, and 
an increased likelihood to be treated with antibiotics. Accordingly, patients living in 
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long-term healthcare facilities are generally older, and having higher chance of being 
exposed to increased antibiotics (Sunenshine and McDonald 2006).   
The disease progression can vary from patient to patient, depending on their 
immune response to CDI. Those patients that produce high antibody titers to toxin A 
usually only develop diarrhea, and have a higher possibility of resolving without 
reoccurrence. On the contrary, failure to produce adequate antibodies to toxins results 
in increased risk for complications and recurrent infections (Kelly 1996, Kyne et al. 
2001). Besides, asymptomatic carriers normally have high antibody titers to toxin A, 
and are unlikely to develop severe symptoms when exposed to antibiotics (Salcedo et 
al. 1997).  
Prior to the emergence of hypervirulent strains of C. difficile, pregnant women 
share an unusual high occurrence rate of CDI, with some minor symptoms not 
involving hospitalization. Now there is an increased frequency and severity of disease 
is associated with CDI in peripartum women, leading to increased colectomies, 
stillbirths and maternal deaths (Rouphael et al. 2008). Those patients admitted to 
hospitals have increased rates of asymptomatic colonization despite of progress to 
infection. Cultures on a variety of surfaces in healthcare facilities have been tested 
and demonstrated high levels of C. difficile contamination (McFarland et al. 1989). In 
screenings of patients upon admission, it has been found that carriage rates have a 
range between 5.9 to 11%, which is higher than the normal distribution in adults of 2 
to 3%.  Infection rates differ among patient groups depending on other risks factors, 
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but overall the rate is between 4 to 21% in a non-outbreak environment. A study in 
one hospital demonstrated an acquisition rate of 13% for patients hospitalized for 1-2 
weeks; the rate increased to 50% based on the hospitalized patients for more than a 
month (Calabi et al. 2002). Approximately 63% of these patients would become 
asymptomatic carriers. What’s more, studies of outbreaks have found acquisition rates 
can rise to as high as 32%, especially when highly susceptible patients are involved 
(Barbut and Petit 2001). It is found that the time needed to treat patients, those who 
developed CDI while being treated for another issue at the same time, could be 
increased by 3.6 days in the hospital, at an estimated cost of over 1 billion dollars in 
the U.S. per year (Kyne et al. 2002). 
1.7 Treatment for CDI 
The first step in treatment of CDI is to stop the current offending antibiotic if 
possible, or switch to another antibiotic with a narrower spectrum. Using this method, 
nearly 25% of diarrhea from mild CDI would be resolved without further 
complication (Barbut et al. 2000). Subsequently, supportive therapy should be 
followed to rehydrate and replace electrolytes, especially in patients with severe 
diarrhea. Antiperistaltic drug therapy should be avoided to limit patients’ exposure to 
C. difficile toxins, which may result in the development of toxic megacolon 
(McFarland 2005). Because of the rise of hypervirulent strains, some physicians may 




Clindamycin is an effective treatment for serious anaerobic infection, but was 
used so widely that it has been gradually losing its efficiency (Kabins and Spira 1975). 
To date, when diarrhea and colitis caused by C. difficile are severe, there are some 
other common effective treatments which are oral metronidazole and oral vancomycin 
(Kelly and LaMont 1998). Besides, ampicillin, amoxicillin, and cephalosporins are 
also some common alternatives concerned with C. difficile (Kelly and LaMont 1998).   
C. difficile strains produce a binary toxin (CDT), apart from toxin A and toxin 
B, and they exhibit a resistance to fluroquinolones and erythromycin (Cartman et al. 
2010). Moreover, treating asymptomatic carriers with metronidazole or vancomycin is 
not ideal, for the treatment may extend the carrier state (Johnson et al. 1992). 
Antibiotics are regarded as the most important risk factor for C. difficile-associated 
diarrhea by reducing ‘colonization resistance’ of the bowel, allowing subsequent 
colonization, and infection with C. difficile (Johnson and Gerding 1998a). Thus, using 
proper antibiotic is of crucial importance, and is also the most effective treatment of C. 
difficile infection. 
Besides, probiotics containing one or several living beneficial microbes have 
also been a popular treatment, either serving as addition to antibiotic therapy or as a 
replacement for antibiotic treatment. The advantages of probiotics are: multiple 
mechanisms of acting on pathogens, benefit to host immune system, survival to host 
colon, no drug interaction, and low risk to the patient, while the drawbacks of 
probiotics are: poor quality control, poor standardization, few clinical trials, possible 
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infections with immunocompromised patients, and sometimes adverse reactions in 
patients (McFarland 2009). 
1.8 C. difficile in food 
C. difficile infection (CDI) essentially occurs in clinic environments, while the 
majority of patients infected by C. difficile are asymptomatic carriers, and one of the 
known risk of infection is sharing a hospital room with an infected patient (Johnson et 
al. 1990). However, in the community, C. difficile is increasingly found among young 
and relatively healthy individuals (Hensgens et al. 2012). In the environment, such as 
soil and water, C. difficile commonly exists. Nevertheless, its presence in numerous 
animals is also ubiquitous, and similar PCR ribotypes are found, particularly ribotype 
027 and ribotype 078 (Rodriguez et al. 2013, Hensgens et al. 2012). Accordingly, 
there may be a potential for transmission from food to humans.  
Community-associated C. difficile infection is increasingly regarded as a 
potential foodborne disease, especially in food animal. A study from USA, examining 
samples from stores in the Tuscon, Arizona area, found isolation of C. difficile from 
37 of 88 samples, including ground beef (13/26), summer sausage (1/7), ground pork 
(3/7), braunschweiger (10/16), chorizo (3/10), pork sausage (3/13), and ground turkey 
(4/9) (Songer et al. 2009). Ribotype 078 was the majority strain, and the rest belonged 
to ribotype 027 (Songer et al. 2009).  
Though infection with retail meat is most compelling, infection with other 
food products may be equally fatal, particularly for those that are not cooked before 
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eating. A research from South Wales described 71% of C. difficile isolates from 
vegetables were toxigenic (al Saif and Brazier 1996b). Reported CDIs associated with 
salad-used-vegetables have also been found in France and Scotland (Bakri et al. 2009, 





CHAPTER II．Prevalence and antibiotic resistance of C. 
difficile in lettuce 
2.1 Introduction 
Clostridium difficile (C. difficile), a species of Gram-positive, spore-forming, 
and anaerobic bacteria, is the causative reason of Clostridium difficile-associated 
diarrhea (CDAD) and can lead to more serious disease such as pseudomembranous 
colitis, toxic megacolon, and even death in humans (Monaghan et al. 2013). 
Pathogenic C. difficile produces two protein exotoxins, toxin A, comprised of 2710 
residues (308.0 kDa), and toxin B, comprised of 2366 residues (269.6 kDa) (Kelly and 
LaMont 1998). Toxin A and B (also called TcdA and TcdB), the primary makers of 
Clostridium difficile infection (CDI), belong to the large clostridial cytotoxins (LCT). 
In addition to toxin A and B, C. difficile strains produce a binary toxin, called C. 
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difficile toxin (CDT). However, only about 6% of C. difficile isolates produce the 
binary toxin, and these are toxinotype variants (Geric et al. 2004). 
In earlier studies, toxin A was regarded as the predominant virulence factor, 
and toxin B alone, without the present of toxin A did not cause disease (1994, 
Pothoulakis et al. 1986) (Voth and Ballard 2005).  As a result, the mechanism of 
toxin B in disease is not well explored as the role of toxin A. With the discoveries of 
some toxinA-toxinB+ strains (King, Mackin, and Lyras 2015), toxin B was reported to 
contribute to the C. difficile–associated diseases, and it was regarded as the essential 
virulence contributor (Lyras, O'Connor, et al. 2009).  
C. difficile infection (CDI) essentially has occured in a clinic environment, 
however, community-associated C. difficile infection is increasingly regarded as a 
potential foodborne disease, especially in food animals (Rodriguez et al. 2014). 
Though infection with retail meat is most compelling but has not been proven 
(Rodriguez et al. 2013), infection with other food products may be equally fatal, 
particularly for those that are not cooked before eating (Weese 2010). Pathogenic C. 
difficile isolated from vegetables has been reported in Europe (al Saif and Brazier 
1996b), while in United States, there is limited research focusing on ready-to-eat 
vegetable such as lettuce. Modified atmphosere packing and storage condition of 
lettuce could promote the growth of anaerobic bacteria such as C. difficile (Doulgeraki, 
Paramithiotis, and Nychas 2011). Furthermore, there are various possible sources of 
lettuce contamination with C. difficile, all of which are likely to be ultimately human 
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or animal, such as soil, fertilizer (manure), water, processing environments, and 
human hands (Simango 2006, Rodriguez et al. 2013, Weese 2010).   
People are more likely to become infected with C. difficile with the use of 
antibiotics, not only because antibiotics disrupt the normal intestinal flora, resulting in 
C. difficile colonization (Kyne et al. 2002), but also C. difficile has been found to be 
resistance to several antibiotics (Owens et al. 2008, Gerding 2004). Antibiotics are 
used to treat bacterial infections, but some antibiotics are found to be ineffective in 
treating the infection of anaerobic bacteria including C. difficile (Lyerly, Krivan, and 
Wilkins 1988). Clindamycin is an effective treatment for serious anaerobic bacterial 
infections, but has been used so widely that it is now gradually losing its efficiency 
(Kabins and Spira 1975). To date, when diarrhea and colitis caused by C. difficile are 
severe, the common effective treatments are oral metronidazole and vancomycin 
(Kelly and LaMont 1998).  
In this study we determined the prevalence and antibiotic resistance of C. 
difficle in lettuce. 
2.2 Materials and Methods 
2.2.1 Sample preparation  
Lettuces, harvested in California, Arkansas, and Louisiana, were continuously 
purchased from retail stores and tested from September 2014 to March 2015. The 
lettuce samples were grown in Salinas, California; Bentonville, Arkansas and Baton 
Rouge, Louisiana. The types of lettuce sample purchased from California, Arkansas, 
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and Louisiana were iceberg lettuce, butter lettuce, and romaine lettuce, respectifully. 
In all, 297 lettuce samples were tested, and for each state, 99 samples were tested (8 
lettuce samples for per month in September, Ocotober, November 2014; 10 lettuce 
samples in December 2014; 15 lettuce samples in January 2015; 20 lettuce samples in 
Feberary 2015; 30 lettuce samples in March 2015)  
Brain Heart Infusion broth (BHI) (BD) supplemented with 0.1% sodium 
taurocolic acid and C. difficile selective supplement (Sigma-Aldrich), containing 
cefoxitin (8 µg/ ml) and D-cycloserine (250 µg/ ml), was used to enrich C. difficile 
isolates, for isolation from the lettuce samples. For each lettuce sample, 60 ml sterile 
BHI supplemented broth and 40 g lettuce were blended together in a filter bag; the 
collection from each sample was done in duplicate. Every filter bag was incubated 
anaerobically by a GasPakTM EZ Anaerobe Pouch System at 37 ⁰C for 10 days.  
2.2.2 Isolation C. difficile 
After the samples were incubated for 10 days, the sample broth in the filter 
bag was transferred into sterile test tubes. To detect the presence of C. difficle, 
BBL™ Clostridium difficile Selective Agar (BD) plates were used, 2 plates per filter 
bag. The plates were reduced anaerobically under room temperature for 24 hours 
before use. Then 0.1 ml of the collected supernatant was streaked onto the selective 
plates under a certified bacteria safety hood and the inverted plates were incubated 
anaerobically, with the anaerobe pouch system mentioned above, at 37 ⁰C for 48 
hours. C. difficile colonies were identified by their morphological and fluorescence 
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properties under long wavelength UV (380 nm) within one hour in the presence of 
oxygen. The positive C. difficile colonies emitted a yellow fluorescence. For further 
research, the C. difficile colonies of each lettuce sample isolated from the C. difficile 
selective plates were collected and stored in –80ºC freezer.   
2.2.3 DNA extraction 
Right after the colonies of C. difficile were observed on the plates, DNA 
extraction was conducted according to the instructions of a commercial DNA 
extraction kit (MO-BIO UltraClean® Microbial DNA Isolation Kit). Three colonies 
from each plate were collected into a sterile 2 ml centrifuge tube. Then the microbial 
cells were resuspended in provided bead solution, they were added to a bead beating 
tube containing beads, followed by lysis solution. With a combination of heat, 
detergent, and mechanical force against specialized beads, the cellular components 
were lysed. C. fifficile DNA was release from the lysed cells, and bound to a silica 
Spin Filter. After washing the filter several times, the DNA was recovered in the 
provided DNA-free Tris buffer. Extracted DNA was stored at −20 ⁰C until real-time 
PCR was performed. 
2.2.4 Real-time PCR assays for toxin A and B  
Non-repeat regions on toxin A and toxin B genes are commonly chosen as 
amplifying-segments in real-time PCR assays. For toxin A detection assay, the primers 
and the probe described by Luna et al. were utilized (Luna et al. 2011); for toxin B 
detection, the real-time PCR method was performed with the primers and the probe 
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specific to determine the virulence of C. difficile isolates in lettuce, which is described 
by van den Berg et al (van den Berg et al. 2005)(Table 1). The total volume of each 
reaction mixture for the Real-time PCR was 25 µl. For the toxin A assay, each 
amplification mixture consisted 12.5 µl Bio-Rad iQTM Supermix (2x), 0.6 µM forward 
primer (tcdAF), 0.6 µM reverse primer (tedAR), 0.1 µM hydrolysis probe (tcdATM), 
PCR grade water, and a 6.25 µl DNA sample. For the toxin B assay, each final 
reaction mixture included 12.5 µl Bio-Rad iQTM Supermix (2x), 0.25 µl of 10 µM 
forward primer (398CLDs), 0.5 µl of 10 µM reverse primer (399CLDs), 0.5 µl of 10 
µM 551CLD-tq-FAM probe, 0.25 µl of 0.1M MgCl2, 8.5 µl PCR water, and 2.5 µl 
DNA template. Amplification was performed using a Cepheid SmartCycler II system 
(Sunnyvale). The cycling program of the toxin A assay was as following: 1 cycle of 
95°C for 10 min; 45 cycles of 95°C for 10 min, 57°C for 20 s, and 72°C for 10 s. For 
toxin B assay, after the reaction mixtures were initially heated for 3 minutes at 95 ⁰C, 
they went through 45 cycles. Each cycle possessed a 30 s denaturation step at 94 ⁰C, a 
30 s annealing step at 57 ⁰C, and a 30 s extension step at 72 ⁰C. Positive and negative 
controls were run in each trial. The extracted DNA (2.5 µl) from a toxin A positive 
toxin B positive C. difficile strain (ATCC 43255) was employed as the positive control, 
and the PCR grade water (2.5 µl) was served as the negative control. 
Table 1. Primers and probes for real-time PCR detection of C. difficile toxin A and B 
Primers and probe Nucleotide sequence (5’- 3’) 
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Toxin A tcdAF GGTAATAATTCAAAAGCGGCT 
 tcdAR AGCATCCGTATTAGCAGGTG 
 tcdATM FAM-AGCCTAATACAGCTATGGGTGCGAA-
AMRA 
Toxin B 398CLDs GAAAGTCCAAGTTTACGCTCAAT 
 399CLDas GCTGCACCTAAACTTACACCA 
 551CLD-tq-FAM  FAM-ACAGATGCAGCCAAAGTTGTTGAAT
T-TAMRA 
 
2.2.5 Antibiotic resistance detection  
The standard NCCLS (National Committee for Clinical Laboratory Standards) 
broth microdilution MIC (minimal inhibitory concentration) test was performed for 
the toxigenic isolates to determine the effect of following antibiotics, clindamycin, 
vancomycin, metronidazole, erythromycin, cefotaxime. For each toxigenic isolates, 
the broth microdilution MIC test was conducted in duplicate. The Mueller-Hinton 
broth (BD) was used, and the pH was adjusted between 7.2 and 7.4. Within 15 min of 
adjusting the inoculum broth to the turbidity of a 0.5 McFarland standard, the 
inoculum suspension was diluted to a final concentration of 5 x 104 CFU/ 0.1 ml well. 
Results were recorded after 20-24 h incubation, and NCCLS interpretive criteria was 
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used to interpret the results: clindamycin, susceptible, ≤2 μg/ml, resistant, ≥ 8 μg/ml; 
vancomycin, susceptible, ≤2 μg/ml, resistant, >2 μg/m; metronidazole, susceptible, ≤8 
μg/ml, resistant, ≥ 32 μg/ml; erythromycin, susceptible, ≤0.5 μg/ml, resistant, ≥ 8 
μg/ml; cefotaxime, susceptible, ≤8 μg/ml, resistant, ≥ 64 μg/ml.  
2.3 Results and Discussions 
2.3.1 Isolation C. difficile  
From Clostridium difficile Selective Agar (CDSA) test, 52 (52.5%) C. difficile 
isolates were detected in 99 California lettuce samples; 44 (44.4%) C. difficile isolates 
were detected 99 Arkansas lettuce samples; 61 (61.6%) C. difficile isolates in 99 
Louisiana lettuce samples (Table 2). Since the selective plates do not have the ability 
to differ the toxigenic isolates from the non-toxigenic ones. The detection of toxin A 
and B was followed to identify the toxigenic strains.  
Table 2. Clostridium difficile isolated from California, Arkansas, and Louisiana 
lettuce samples between September 2014 and March 2015 
State 
tested 
 Sep Oct Nov Dec Jan Feb Mar Total (%) 
California PO
S 
2 5 7 3 7 11 17 52 (52.5%) 
N 8 8 8 10 15 20 30 99 




N 8 8 8 10 15 20 30 99 
Louisiana PO
S 
0 3 6 3 8 16 25 61 (61.6%) 
N 8 8 8 10 15 20 30 99 
POS, the number of the sample having positive result from CDSA test. N, the total 
number of the sample tested. 
2.3.2 Real-time PCR assays for toxin A and B   
Since naturally occurring toxin A positive B negative isolates have not been 
reported so far (Lyras, O'Connor, et al. 2009), to determine the prevalence of the C. 
difficile isolates found in lettuce samples, toxin B real-time PCR assay was conducted. 
According to the results from toxin B detection (Table 3), 15 Clostridium difficile 
toxigenic isolates were detected in 99 samples from California; 10 Clostridium 
difficile toxigenic isolates were detected in 99 samples from Arkansas; 16 Clostridium 
difficile toxigenic isolates were detected in 99 samples from Louisiana.  
The samples were continuously purchased and tested from September 2014 to 
March 2015. To determine whether there is a close relationship between the 
temperatures of the months (Figure 5) and the frequency of the toxigenic isolates 
presence from California, Arkansas, and Louisiana, a linear regression model was 
tested. The p values of the results from California, Arkansas, and Louisiana were 
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0.645, 0.0561, and 0.6659 larger than 0.05. The hypnosis was denied, meaning there 
was no direct relationship between these two. 
Table 3. The positive result from real-time PCR for toxin B detection of C. difficile 




 Sep Oct Nov Dec Jan Feb Mar Total 
(%) 
California POS 2 1 3 1 0 5 3 15 
(15.2%) 
N 8 8 8 10 15 20 30 99 
Arkansas POS 0 2 1 1 2 4 0 10 
(10.1%) 
N 8 8 8 10 15 20 30 99 
Louisiana POS 0 2 0 1 0 11 2 16 
(16.2%) 
N 8 8 8 10 15 20 30 99 
POS, the number of the sample having positive result from toxin B real-time 
PCRassay. N, the total number of the sample tested. 
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The toxin A real-time PCR results were recorded, combined with the results 
from toxin B detection assay (Table 4). Overall, 41 toxigenic isolates were detected 
from 297 samples; and among the 41 toxigenic isolates, there were 7 toxin A negative 
toxin B positive isolates. The totally percentage of the toxigenic C. difficle isolates 
found in lettuce samples was 13.8%, this was higher than the other reported results 
(Al Saif and Brazier 1996a, Bakri et al. 2009, Metcalf et al. 2010, Rodriguez-Palacios, 
Ilic, and LeJeune 2014). Previous scientific studies have concentrated on testing 
several types of vegetables including lettuce for toxigenic C. difficle. A study 
conduction in 2014, tested 125 different vegetables that included 41 lettuce samples 
for toxigenic C. difficle. The vegetable samples were from several retail stores located 
in Ohio and had originated from several states in the USA and Mexico.  The results 
of their study found 1 positive toxigenic C. difficle isolate in the 41 lettuce samples 
Figure 5. The growth temperature of the sample lettuces harvested from California, 
Arkansas, and Louisiana between September 2014 and March 2015. 
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tested. (Rodriguez-Palacios, Ilic, and LeJeune 2014). Another study, reported 7.5% C. 
difficile prevalence in ready-to-eat salad in Scotland, they collected 40 packaged 
lettuce samples over one month from 7 different supermarkets (Bakri et al. 2009). 
These previous studies detected lower C. difficile prevalence in lettuce than this study 
possibly due to a small sample size and purchase location. (Bakri et al. 2009, Al Saif 
and Brazier 1996a, Metcalf et al. 2010, Rodriguez-Palacios, Ilic, and LeJeune 2014).  
In addition, contamination of lettuce with C. difficile spores would not only be 
due to attachment on the leaves from contaminated water or soil (Simango 2006), but 
also would widely exist in the downstream production chain including storage, 
transportation, and handling environments (Rodriguez et al. 2013). Since the same 
varieties and brand of lettuces tested for toxigenic C. difficle came from the same 
processor located in California, Arkansas, and Louisiana, if the processing 
environment was exposed to toxigenic C. difficile spores, it would largely increase the 
presence of the C. difficile spores on the lettuce samples and thus increase the 
prevalence. 
Table 4. Real-time PCR profile of C. difficile isolates in lettuce samples among the 
states tested 




3 12 15 (15.1%) 
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Arkansas, n=99 2 8 10 (10.1%) 
Louisiana, 
n=99 
2 14 16 (16.2%) 
Total 7/297 (2.4%) 34/297 (11.4%) 41/297 
(13.8%) 
 
2.3.3 Antibiotic resistance detection 
Five antibiotics, metronidazole, vancomycin, clindamycin, erythromycin, and 
cefotaxime (Table 5), were tested for the toxigenic C. difficile isolates. Among the 
antibiotics we tested, all the 41 isolates were resistant or intermediately resistant to all 
the 5 antibiotics, while 37 isolates and 26 isolates showed intermediately resistance to 
clindamycin and cefotaxime. The resistance and intermediately resistance properties 
of the isolates for clindamycin and cefotaxime were in accord with the findings from 
other C. difficile vegetable isolates (Bakri et al. 2009). However, metronidazole, 
vancomycin, and erythromycin did not have the susceptive effect to the isolates as 
being reported (Bakri et al. 2009, Metcalf et al. 2010). Since the antibiotic resistance 
property of C. difficile would vary depending on the location (Metcalf et al. 2010), the 
different antibiotics effect would be understandable. Since no antibiotic resistance 
pattern remain consistent enough to be used as a C. difficile strain marker (Tenover, 
Tickler, and Persing 2012), the different antibiotics effect in this study would be 
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understandable. Besides, two same toxigenic C. difficile isolates from the same kind 
of vegetable were reported to have different antibiotic susceptibility to a certain 
antibiotic (Metcalf et al. 2010).  
Table 5. Susceptibility of the C. difficile isolates to 5 antibiotics 
Agent 
MIC (μg/ml) No. (%) of isolates 
Range 50% 90% Susceptible Intermediate Resistant 
Metronidazole 0.125-80 >80 >80 0 (0) 0 (0) 41 (100) 
Vancomycin 0.25–4 4 >4 0 (0) 0 (0) 41 (100) 
Clindamycin  1-16 4 8 0 (0) 37 (90.2) 4 (9.8) 
Erythromycin  1-16 16 >16 0 (0) 0 (0) 41 (100) 
Cefotaxime 6-64 12 24 0 (0) 26 (63.4) 15 (36.6) 
50%, the antibiotic concentration when 50% growth of the tested C. difficle isolate 
inhibited. 90%, the antibiotic concentration when 90% growth of the tested C. difficle 
isolate inhibited.  
2.4 Conclusions 
The C. difficile isolated from the retail lettuce has a high possibility to be 
toxigenic. Although the public health relevance is still unclear, consumption retail 
vegetables as salad vegetable or without high-temperature processed might be a 
source of C. difficile infection. Treated with five different antibiotics, the C. difficile 
sample isolates expressed strong resistance to metronidazole, vancomycin, and 
erythromycin. This present research contributes in revealing a possible source of 
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